KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Moderna (MRNA) Invested Capital (2016 - 2025)

Moderna (MRNA) has disclosed Invested Capital for 9 consecutive years, with $8.7 billion as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital fell 20.69% to $8.7 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $8.7 billion, a 20.69% decrease, with the full-year FY2025 number at $8.7 billion, down 20.69% from a year prior.
  • Invested Capital was $8.7 billion for Q4 2025 at Moderna, down from $9.4 billion in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $20.2 billion in Q4 2022 to a low of $25.0 million in Q1 2025.
  • A 5-year average of $12.5 billion and a median of $13.0 billion in 2024 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: surged 424.82% in 2021, then plummeted 99.81% in 2025.
  • Moderna's Invested Capital stood at $14.1 billion in 2021, then soared by 42.78% to $20.2 billion in 2022, then tumbled by 31.4% to $13.9 billion in 2023, then decreased by 20.87% to $11.0 billion in 2024, then decreased by 20.69% to $8.7 billion in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Invested Capital are $8.7 billion (Q4 2025), $9.4 billion (Q3 2025), and $9.5 billion (Q2 2025).